Parkinson's Disease

Department of Health written question – answered on 23rd February 2015.

Alert me about debates like this

Photo of Mary Macleod Mary Macleod Conservative, Brentford and Isleworth

To ask the Secretary of State for Health, what progress the Clinical Priorities Action Group has made in the review of the treatment duodopa for Parkinson's disease; and how the views of those affected by Parkinson's disease are being taken into account in that review.

Photo of George Freeman George Freeman The Parliamentary Under-Secretary of State for Business, Innovation and Skills, The Parliamentary Under-Secretary of State for Health

NHS England has advised that, at the request of patient groups, NHS England is currently consulting with patients and the wider public about how it makes decisions on which specialised services and treatments, including Duodopa, to invest in. This will ensure the principles and process it follows are well informed, evidence-led and in line with the expectations of patients and the public.

The consultation runs until 27 April 2015 and can be found at:

www.engage.england.nhs.uk/consultation/investing-in-specialised-commissioning

Until then, any decision that is urgent on clinical grounds will be dealt with quickly though NHS England’s existing procedures. Clinicians will continue to be able to make Individual Funding Requests, on behalf of their patients, to NHS England for treatments like Duodopa that are not routinely available.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.